DRUGS & SUPPLEMENTS
What is the dose of the medication you are taking?
Carbidopa is indicated for use with carbidopa-levodopa or with levodopa in the treatment of
the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system
by carbon monoxide intoxication and/or manganese intoxication.
Carbidopa is for use with carbidopa-levodopa in patients for whom the dosage of
carbidopa-levodopa provides less than adequate daily dosage (usually 70 mg daily) of
Carbidopa is for use with levodopa in the occasional patient whose dosage requirement of
Carbidopa and levodopa necessitates separate titration of each medication.
Carbidopa is used with carbidopa-levodopa or with levodopa to permit the administration
of lower doses of levodopa with reduced nausea and vomiting, more rapid dosage titration,
and with a somewhat smoother response. However, patients with markedly irregular (“on-off”)
responses to levodopa have not been shown to benefit from the addition of Carbidopa.
Since Carbidopa prevents the reversal of levodopa effects caused by pyridoxine, supplemental
pyridoxine (vitamin B6), can be given to patients when they are receiving Carbidopa and
levodopa concomitantly or as carbidopa-levodopa.
Although the administration of Carbidopa permits control of parkinsonism and Parkinson’s
disease with much lower doses of levodopa, there is no conclusive evidence at present that this
is beneficial other than in reducing nausea and vomiting, permitting more rapid titration, and providing a somewhat smoother response to levodopa.
Certain patients who responded poorly to levodopa alone have improved when Carbidopa and
levodopa were given concurrently. This was most likely due to decreased peripheral decarboxylation of levodopa rather than to a primary effect of Carbidopa on the peripheral
nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa.
In deciding whether to give Carbidopa with carbidopa-levodopa or with levodopa to patients who have nausea and/or vomiting, the physician should be aware that, while many patients may be expected to improve, some may not. Since one cannot predict which patients are likely to improve, this can only be determined by a trial of therapy. It should be further noted that in controlled trials comparing Carbidopa and levodopa with levodopa alone, about half the patients with nausea and/or vomiting on levodopa alone improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial.
Carbidopa is contraindicated in patients with known hypersensitivity to any component of this drug.
Nonselective monoamine oxidase (MAO) inhibitors are contraindicated for use with levodopa or carbidopa-levodopa combination products with or without Carbidopa. These inhibitors must be discontinued at least two weeks prior to initiating therapy with levodopa. Carbidopa-levodopa, or levodopa may be administered concomitantly with the manufacturer’s recommended dose of an MAO inhibitor with selectivity for MAO type B (e.g., selegiline HCl) (see PRECAUTIONS, Drug Interactions ).
Levodopa or carbidopa-levodopa products, with or without Carbidopa, are contraindicated in patients with narrow-angle glaucoma.
Carbidopa has no antiparkinsonian effect when given alone. It is indicated
for use with carbidopa-levodopa or levodopa. Carbidopa (carbidopa) does not decrease
adverse reactions due to central effects of levodopa.
When Carbidopa (carbidopa) is to be given to carbidopa-naive patients who are being treated with levodopa alone, the two drugs should be given at the same time. At least twelve hours should elapse between the last dose of levodopa and initiation of therapy with Carbidopa (carbidopa) and levodopa in combination. Start with no more than one-fifth (20%) to one-fourth (25%) of the previous daily dosage of levodopa when given without Carbidopa (carbidopa). See the DOSAGE AND ADMINISTRATION section before initiating therapy.
The addition of Carbidopa with levodopa or carbidopa-levodopa reduces the peripheral
effects (nausea, vomiting) due to decarboxylation of levodopa; however, Carbidopa does
not decrease the adverse reactions due to the central effects of levodopa. Because Carbidopa permits more levodopa to reach the brain and more dopamine to be formed,
certain adverse central nervous system (CNS) effects, e.g., dyskinesias (involuntary
movements), may occur at lower dosages and sooner with levodopa in combination with
Carbidopa than with levodopa alone.
Falling Asleep During Activities of Daily Living and Somnolence
Patients taking carbidopa-levodopa products alone or with other dopaminergic drugs have
reported suddenly falling asleep without prior warning of sleepiness while engaged in activities
of daily living (includes operation of motor vehicles). Some of these episodes resulted in
automobile accidents. Although many of these patients reported somnolence while on
dopaminergic medications, some did perceive that they had no warning signs, such as excessive
drowsiness, and believed that they were alert immediately prior to the event. Some patients
reported these events one year after the initiation of treatment.
Falling asleep while engaged in activities of daily living usually occurs in patients experiencing
pre-existing somnolence, although some patients may not give such a history. For this reason,
prescribers should continually reassess patients for drowsiness or sleepiness especially since
some of the events occur after the start of treatment. Prescribers should be aware that patients
may not acknowledge drowsiness or sleepiness until directly questioned about drowsiness or
sleepiness during specific activities. Patients who have already experienced somnolence or an
episode of sudden sleep onset should not participate in these activities during treatment with
Carbidopa when taking it with other carbidopa-levodopa products.
Before initiating treatment with Carbidopa, advise patients about the potential to develop
drowsiness and ask specifically about factors that may increase the risk for somnolence with
Carbidopa such as the use of concomitant sedating medications and the presence of sleep
disorders. Consider discontinuing Carbidopa in patients who report significant daytime
sleepiness or episodes of falling asleep during activities that require active participation (e.g.,
conversations, eating, etc.). If treatment with Carbidopa continues, patients should be advised
not to drive and to avoid other potentially dangerous activities that might result in harm if the
patients become somnolent. There is insufficient information to establish that dose reduction
will eliminate episodes of falling asleep while engaged in activities of daily living.
Sporadic cases of a symptom complex resembling neuroleptic malignant syndrome (NMS) have
been reported in association with dose reductions or withdrawal of certain antiparkinsonian
agents such as levodopa, carbidopa-levodopa, or carbidopa-levodopa extended release. Therefore, patients should be observed carefully when the dosage of levodopa or carbidopa-levodopa is reduced abruptly or discontinued, especially if the patient is receiving
NMS is an uncommon but life-threatening syndrome characterized by fever or hyperthermia.
Neurological findings, including muscle rigidity, involuntary movements, altered
consciousness, mental status changes; other disturbances, such as autonomic dysfunction,
tachycardia, tachypnea, sweating, hyper- or hypotension; laboratory findings, such as creatine phosphokinase elevation, leukocytosis, myoglobinuria, and increased serum myoglobin, have been reported.
The early diagnosis of this condition is important for the appropriate management of these
patients. Considering NMS as a possible diagnosis and ruling out other acute illnesses
(e.g., pneumonia, systemic infection, etc.) is essential. This may be especially complex if the
clinical presentation includes both serious medical illness and untreated or inadequately treated
extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central
nervous system (CNS) pathology.
The management of NMS should include: 1) intensive symptomatic treatment and medical
monitoring and 2) treatment of any concomitant serious medical problems for which specific
treatments are available. Dopamine agonists, such as bromocriptine, and muscle relaxants,
such as dantrolene, are often used in the treatment of NMS; however, their effectiveness has
not been demonstrated in controlled studies.
As with levodopa alone, periodic evaluations of hepatic, hematopoietic, cardiovascular, and
renal function are recommended during extended concomitant therapy with Carbidopa and
levodopa, or with Carbidopa and carbidopa-levodopa, or any combination of these drugs.
Postmarketing reports suggest that patients treated with anti-Parkinson medications can
experience intense urges to gamble, increased sexual urges, intense urges to spend money
uncontrollably, binge eating, and other intense urges. Patients may be unable to control these
urges while taking one or more of the medications that are used for the treatment of Parkinson’s
disease and that increase central dopaminergic tone, including Carbidopa taken with levodopa and
Carbidopa. In some cases, although not all, these urges were reported to have stopped when the
dose of anti-Parkinson medications was reduced or discontinued. Because patients may not
recognize these behaviors as abnormal it is important for prescribers to specifically ask patients
or their caregivers about the development of new or increased gambling urges, sexual urges,
uncontrolled spending or other urges while being treated with Carbidopa. Physicians should
consider dose reduction or stopping Carbidopa or levodopa if a patient develops such urges while
taking Carbidopa with carbidopa/levodopa.
Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.
In general, hallucinations present shortly after the initiation of therapy and may be responsive to
dose reduction in levodopa. Hallucinations may be accompanied by confusion and to a lesser
extent sleep disorder and excessive dreaming. Carbidopa when taken with
carbidopa-levodopa may have similar effects on thinking and behavior. This abnormal thinking
and behavior may present with one or more symptoms, including paranoid ideation, delusions,
hallucinations, confusion, psychotic-like behavior, disorientation, aggressive behavior,
agitation, and delirium.
Ordinarily, patients with a major psychotic disorder should not be treated with Carbidopa and
carbidopa-levodopa, because of the risk of exacerbating psychosis. In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson’s disease and
may decrease the effectiveness of Carbidopa.
Carbidopa (carbidopa) may potentiate the dopaminergic side effects of levodopa and may
cause or exacerbate preexisting dyskinesia.
Patients treated with Carbidopa and carbidopa-levodopa should be observed carefully for the
development of depression with concomitant suicidal tendencies.
Epidemiological studies have shown that patients with Parkinson’s disease have a higher risk
of developing melanoma than the general population.
Whether the observed increased risk was due to Parkinson’s disease or other factors, such as drugs used to treat Parkinson’s disease, is unclear.
For the reasons stated above, patients and providers are advised to monitor for melanomas
frequently and on a regular basis when using Carbidopa tablets for Parkinson’s disease.
Ideally, periodic skin examinations should be performed by appropriately qualified individuals
It is important that Carbidopa with levodopa be taken at regular intervals according to the
schedule outlined by the health care provider. Caution patients not to change the prescribed
dosage regimen and not to add any additional antiparkinson medications, including other
carbidopa-levodopa preparations without first consulting a physician.
Advise patients that sometimes a “wearing-off” effect may occur at the end of the dosing
interval. Tell patients to notify the prescriber if such response poses a problem to lifestyle.
Patients should be advised that occasionally dark color (red, brown, or black) may appear in
saliva, urine, or sweat after ingestion of Carbidopa and levodopa. Although the color appears
to be clinically insignificant, garments may become discolored.
The patient should be advised that a change in diet to foods that are high in protein may delay
the absorption of levodopa and may reduce the amount taken up in the circulation. Excessive acidity also delays stomach emptying thus delaying the absorption of levodopa. Iron salts (such as in multivitamin tablets) may also reduce the amount of levodopa available in the body. The above factors may reduce the clinical effectiveness of the Carbidopa and levodopa therapy.
Alert patients to the possibility of sudden onset of sleep during daily activities, in some cases
without awareness or warning signs, when they are taking dopaminergic agents, including
levodopa. Advise patients to exercise caution while driving or operating machinery and that if
they have experience somnolence and/or sudden sleep onset, they must refrain from these
activities. (See WARNINGS, Falling Asleep During Activities of Daily Living and Somnolence).
There have been reports of patients experiencing intense urges to gamble, increased sexual
urges, and other intense urges, and the inability to control these urges while taking one or more of the medications that increase central dopaminergic tone and that are generally used for the treatment of Parkinson’s disease, including Carbidopa and levodopa. Although it is not proven that the medications caused these events, these urges were reported to have stopped in some cases when the dose was reduced or the medication was stopped. Prescribers should ask patients about the development of new or increased gambling urges, sexual urges, or other intense urges while taking Carbidopa and levodopa. Physicians should consider dose reduction or stopping Carbidopa if a patient develops such urges while taking Carbidopa with carbidopa/levodopa (See PRECAUTIONS, Impulse Control/Compulsive Behaviors).
Abnormalities in laboratory tests may include elevations of liver function tests such as alkaline phosphatase, SGOT, SGPT (ALT), lactic dehydrogenase, and bilirubin. Abnormalities in blood urea nitrogen and positive Coombs test have also been reported. Commonly, levels of blood urea nitrogen, creatinine, and uric acid are lower during concomitant administration of Carbidopa and levodopa than with levodopa alone.
Levodopa and carbidopa-levodopa combination products may cause a false-positive reaction for
urinary ketone bodies when a test tape is used for determination of ketonuria. This reaction will
not be altered by boiling the urine specimen. False-negative tests may result with the use of
glucose-oxidase methods of testing for glucosuria.
Caution should be exercised when the following drugs are administered concomitantly with Carbidopa (carbidopa) given with levodopa or carbidopa-levodopa fixed dose combination products.
Symptomatic postural hypotension has occurred when Carbidopa, given with levodopa or
carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. Therefore, when therapy with Carbidopa, given with or without levodopa or carbidopa-levodopa combination products, is started, dosage adjustment of
the antihypertensive drug may be required.
For patients receiving monoamine oxidase inhibitors (Type A or B), (see CONTRAINDICATIONS). Concomitant therapy with selegiline or rasigiline and Carbidopa and carbidopa-levodopa may be associated with severe orthostatic hypotension not attributable to carbidopa-levodopa alone (see CONTRAINDICATIONS ).
There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and carbidopa-levodopa preparations.
Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa. In addition, the beneficial effects of levodopa in Parkinson's disease have been reported to be reversed by phenytoin and papaverine. Patients taking these drugs with Carbidopa and levodopa or carbidopa-levodopa combination products should be carefully observed for loss of therapeutic response.
Carbidopa and iron salts or multivitamins containing iron salts should be coadministered
with caution. Iron salts can form chelates with levodopa and Carbidopa and
consequently reduce the bioavailability of Carbidopa and levodopa.
Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.
There were no significant differences between treated and control rats with respect to
mortality or neoplasia in a 96-week study of Carbidopa at oral doses of 25, 45, or 135
mg/kg/day. Combinations of Carbidopa and levodopa were
given orally to rats for 106 weeks. No effect on mortality or incidence and type of neoplasia
was seen when compared to concurrent controls.
Mutagenicity studies have not been performed with either Carbidopa or the combination of Carbidopa and levodopa.
Carbidopa had no effect on the mating performance, fertility, or survival of the young when administered orally to rats at doses of 30, 60, or 120 mg/kg/day. The highest dose caused a moderate decrease in body weight gain in males.
The administration of carbidopa-levodopa at dose levels of 10-20, 10-50, or 10-100 mg/kg/day did not adversely affect the fertility of male or female rats, their reproductive performance, or the growth and survival of the young.
There are no adequate and well-controlled studies with Carbidopa in pregnant women. It has been reported from individual cases that levodopa crosses the human placental barrier, enters the fetus, and is metabolized. Carbidopa concentrations in fetal tissue appeared to be minimal. Carbidopa should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Carbidopa, at doses as high as 120 mg/kg/day, was without teratogenic effects in the mouse or rabbit. In the rabbit, but not in the mouse, carbidopa-levodopa produced visceral anomalies, similar to those seen with levodopa alone, at approximately 7 times the maximum recommended human dose. The teratogenic effect of levodopa in rabbits was unchanged by the concomitant administration of Carbidopa.
It is not known whether Carbidopa is excreted in human milk. Because many drugs are excreted in human milk, and because of their potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the nursing woman.
Safety and effectiveness in pediatric patients have not been established, and use of the drug in patients below the age of 18 is not recommended.
Clinical studies of Carbidopa did not include sufficient numbers of subjects aged 65 and over
to determine whether they respond differently from younger subjects. Other clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease and other drug therapy.
Carbidopa has not been demonstrated to have any overt pharmacodynamic actions in the recommended doses. The only adverse reactions that have been observed have been with concomitant use of Carbidopa with other drugs such as levodopa, and with carbidopa-levodopa combination products.
When Carbidopa is administered concomitantly with levodopa or carbidopa-levodopa combination products, the most common adverse reactions have included dyskinesias such as choreiform, dystonic, and other involuntary movements, and nausea. Other adverse reactions reported with Carbidopa when administered concomitantly with levodopa alone or carbidopa-levodopa combination products were psychotic episodes including delusions, hallucinations, and paranoid ideation, depression with or without development of suicidal tendencies, and dementia. Convulsions also have occurred; however, a causal relationship with concomitant use of Carbidopa and levodopa has not been established.
The following other adverse reactions have been reported with levodopa and carbidopa-levodopa combination products. These same adverse reactions may also occur when Carbidopa is administered with these products.
Body as a Whole: abdominal pain and distress, asthenia, chest pain, fatigue.
Cardiovascular: cardiac irregularities, hypertension, myocardial infarction, hypotension including orthostatic hypotension, palpitation, phlebitis, syncope.
Gastrointestinal: anorexia, bruxism, burning sensation of the tongue, constipation, dark saliva, development of duodenal ulcer, diarrhea, dry mouth, dyspepsia, dysphagia, flatulence, gastrointestinal bleeding, gastrointestinal pain, heartburn, hiccups, sialorrhea, taste alterations, vomiting.
Hematologic: hemolytic and non-hemolytic anemia, leukopenia, thrombocytopenia, agranulocytosis.
Hypersensitivity: angioedema, urticaria, pruritus, Henoch-Schonlein purpura, bullous lesions (including pemphigus-like reactions).
Metabolic: edema, weight gain, weight loss.
Musculoskeletal: back pain, leg pain, muscle cramps, shoulder pain.
Nervous System/Psychiatric: Psychotic episodes including delusions, hallucinations and
paranoid ideation, NMS,( see WARNINGS), bradykinetic
episodes (“on-off” phenomenon), confusion, agitation, dizziness, somnolence, dream
abnormalities including nightmares, insomnia, paresthesia, headache, depression with or without
development of suicidal tendencies, dementia, pathological gambling, increased libido including
hypersexuality, impulse control symptoms. Convulsions also have occurred; however, a causal
relationship with Carbidopa and levodopa, has not been established.
Respiratory: upper respiratory infection, dyspnea, pharyngea pain, cough.
Skin: flushing, increased sweating, malignant melanoma (see CONTRAINDICATIONS ), rash, alopecia, dark sweat.
Special Senses: oculogyric crises, diplopia, blurred vision, dilated pupils.
Urogenital: dark urine, priapism, urinary frequency, urinary incontinence, urinary retention, urinary tract infection.
Laboratory Tests: abnormalities in alkaline phosphatase, SGOT (AST), SGPT (ALT), lactic dehydrogenase, bilirubin, blood urea nitrogen (BUN), Coombs test; elevated serum glucose; decreased hemoglobin and hematocrit; decreased white blood cell count and serum potassium; increased serum creatinine and uric acid; white blood cells, bacteria and blood in the urine; protein and glucose in the urine.
Miscellaneous: bizarre breathing patterns, faintness, hoarseness, hot flashes, malaise, neuroleptic malignant syndrome, sense of stimulation.
To report SUSPECTED ADVERSE REACTIONS, contact Valeant Pharmaceuticals North America LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
No reports of overdose with Carbidopa have been received. Management of overdosage with Carbidopa is the same as that with levodopa or carbidopa-levodopa preparations.
In the event of overdosage, general supportive measures should be employed, along with immediate gastric lavage. Intravenous fluids should be administered judiciously, and an adequate airway maintained. Electrocardiographic monitoring should be instituted and the patient carefully observed for the development of arrhythmias; if required, appropriate antiarrhythmic therapy should be given. The possibility that the patient may have taken other drugs as well as Carbidopa should be taken into consideration. To date, no experience has been reported with dialysis; hence, its value in overdosage is not known. Pyridoxine is not effective in reversing the actions of Carbidopa.
Based on studies in which high doses of levodopa and/or Carbidopa were administered, a significant proportion of rats and mice given single oral doses of levodopa of approximately 1500-2000 mg/kg are expected to die. A significant proportion of infant rats of both sexes are expected to die at a dose of 800 mg/kg. A significant proportion of rats are expected to die after treatment with similar doses of Carbidopa. The addition of Carbidopa in a 1:10 ratio with levodopa increases the dose at which a significant proportion of mice are expected to die to 3360 mg/kg.
Whether given with carbidopa-levodopa or with levodopa, the optimal daily dose of
Carbidopa must be determined by careful titration. Most patients respond to a 1:10
proportion of Carbidopa and levodopa, provided the daily dosage of Carbidopa is 70 mg or
more a day. The maximum daily dosage of Carbidopa should not exceed 200 mg, since
clinical experience with larger dosages is limited. If the patient is taking carbidopa-levodopa,
the amount of Carbidopa in carbidopa-levodopa should be considered when calculating the
total amount of Carbidopa to be administered each day.
Some patients taking carbidopa-levodopa may not have adequate reduction in nausea and
vomiting when the dosage of Carbidopa is less than 70 mg a day, and the dosage of levodopa
is less than 700 mg a day. When these patients are taking carbidopa-levodopa, 25 mg of Carbidopa may be given with the first dose of carbidopa-levodopa each day. Additional doses of 12.5 mg or 25 mg may be given during the day with each dose of carbidopa-levodopa. Carbidopa may be given with any dose of carbidopa-levodopa as required for optimum therapeutic response. The maximum daily dosage of Carbidopa, given as Carbidopa
and as carbidopa-levodopa, should not exceed 200 mg.
Although carbidopa-levodopa is the most frequently used of Carbidopa and levodopa
administration, there may be an occasional patient who requires individually titrated doses of
these two drugs. In these patients, Carbidopa should be initiated at a dosage
of 25 mg three or four times a day. The two drugs should be given at the same time,
starting with no more than one-fifth (20%) to one-fourth (25%) of the previous or
recommended daily dosage of levodopa when given without Carbidopa (carbidopa). In
patients already receiving levodopa therapy, at least twelve hours should elapse between
the last dose of levodopa and initiation of therapy with Carbidopa (carbidopa) and
levodopa. A convenient way to initiate therapy in these patients is in the morning
following a night when the patient has not taken levodopa for at least twelve hours.
Health care providers who prescribe separate doses of Carbidopa and levodopa should be
thoroughly familiar with the directions for use of each drug.
Dosage of Carbidopa may be adjusted by adding or omitting one-half or one tablet a day. Because both therapeutic and adverse responses occur more rapidly with combined therapy than when only levodopa is given, patients should be monitored closely during the dose adjustment period. Specifically, involuntary movements will occur more rapidly when Carbidopa and levodopa are given concomitantly than when levodopa is given without Carbidopa. The occurrence of involuntary movements may require dosage reduction. Blepharospasm may be a useful early sign of excess dosage in some patients.
Current evidence indicates other standard antiparkinsonian drugs may be continued while Carbidopa and levodopa are being administered. However, the dosage of such other standard antiparkinsonian drugs
may require adjustment.
Sporadic cases of hyperpyrexia and confusion have been associated with dose reductions and
withdrawal of carbidopa-levodopa) or carbidopa-levodopa extended release. Patients should
be observed carefully if abrupt reduction or discontinuation of carbidopa-levodopa or
carbidopa-levodopa extended release is required, especially if the patient is receiving
neuroleptics. (See WARNINGS .)
If general anesthesia is required, therapy may be continued as long as the patient is permitted to take fluids and medication by mouth. When therapy is interrupted temporarily, the patient should be observed for symptoms resembling NMS, and the usual daily dosage may be resumed as soon as the patient is able to take medication orally.
Carbidopa Tablets, 25 mg, are orange, round, compressed tablets that are scored and coded
711 on one side and Carbidopa on the other.
They are supplied as follows:
NDC 25010-711-15 bottles of 100.
Store at 25°C (77°F), excursions permitted to 15°-30°C (59°-86°F).
Aton Pharma, Inc., a division of
Valeant Pharmaceuticals North America LLC
Bridgewater, NJ 08807 USA
Valeant Pharmaceuticals International, Inc.
Steinbach, MB R5G 1Z7, Canada
Carbidopa is a trademark of Valeant Pharmaceuticals International, Inc. or its affiliates.
©Valeant Pharmaceuticals North America LLC
9379201-20001843 Rev. 02/17
Each tablet contains
25 mg of Carbidopa (anhydrous equivalent).
|Carbidopa powder||27.54 USD|
|Lodosyn 25 mg tablet||2.53 USD|
Depending on the reaction of the Carbidopa after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Carbidopa not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.Is Carbidopa addictive or habit forming?
Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
There are no reviews yet. Be the first to write one!
The information was verified by Dr. Rachana Salvi, MD Pharmacology